Shire plc, the global specialty biopharmaceutical company, presented positive new data from a Phase 3 clinical trial designed to evaluate the efficacy of VPRIV compared with imiglucerase in patients with type 1 Gaucher disease.
DARA BioSciences, Inc. announced that it has successfully completed a Phase 1 clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 diabetes.
RapidPick ‘Lite’ is for users who need high speed colony-picking but don't wish to couple the automated plate-handling and picking/re-arraying functions with the RapidPick's immediate pre-pick media filling and immediate post-pick sealing of the growth/daughter plate.
Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences announced the release of its new high-speed and sensitive Evolve 128 EMCCD camera.
Clinical Research Advantage, Inc., a provider of a range of research services to pharmaceutical companies and clinical research organizations, announced its expansion into the Omaha/Council Bluffs market with the opening of three local area offices.
Pfenex Inc. announced the launch of a new business division, Reagent Proteins. Reagent Proteins will enhance the development scientists’ ability to source complex reagent grade proteins at a competitive price.
Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well.
Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.
For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C–specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response rate.
Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has determined that additional time is required to complete the review of the biologics license application for ipilimumab in pre-treated advanced melanoma.
Algeta ASA presented an analysis based on clinical experience with Alpharadin from its phase 1 and phase 2 programs. The analysis concluded that Alpharadin is safe and easy to use, requires no specialized equipment, and is convenient for patients.
Medtronic, the world's largest medical device maker, said it received U.S. regulatory approval for an implant to prevent a type of aneurysm caused by ruptures of the aortic artery.
Parkinson's disease may stem from an energy crisis in the brain. If true, it points to a new approach for Parkinson's: Giving a boost to a key power switch inside brain cells in hopes of slowing the disease's inevitable march instead of just treating symptoms.
A French doctor hired as an adviser on a clinical trial for a liver disease drug passed along secrets about the results, including information about a death, to a hedge fund portfolio manager who dodged $30 million in losses as a result.